Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Institutional investors own 1.5 Billion shares of the 1.6 Billion available
You may be right
Anyone know any info about the conference?
Presenting at conference tonight, I expect either an afternoon pop or a pop tomorrow! GLTA
Posted on Yahoo, not from the company, but a PR nonetheless.
I’m in @ .19
HUGE NEWS
VistaGen Therapeutics to Present at Oppenheimer's 28th Annual Healthcare Conference on March 21, 2018
Marketwired
MarketwiredMarch 5, 2018
SOUTH SAN FRANCISCO, CA--(Marketwired - March 05, 2018) - VistaGen Therapeutics Inc. (VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) disorders, announced today that Shawn Singh, Chief Executive Officer, will present at Oppenheimer's 28th Annual Healthcare Conference in New York City at 8:00 a.m. Eastern Time on Wednesday, March 21, 2018.
For more information about the conference, or to schedule a one-on-one meeting with VistaGen's management, please contact your Oppenheimer representative directly, or visit the conference website: https://www.opco.com/conferences/nyhealthcare18/index.aspx.
1.45 in the after hours
Still holding!
we currently anticipate that Mytesi® gross sales for the period of January 1, 2017 through March 31, 2018 will total approximately $3.2 million.
Boom!
JAGX NEWS
Jaguar Health Subsidiary, Napo Pharmaceuticals, Signs Agreement with Pharmacy Services Provider "Transition Patient Services" to Establish Nationwide Pilot "Mytesi Direct" Program
ACCESSWIRE
ACCESSWIREMarch 2, 2018
SAN FRANCISCO, CA / ACCESSWIRE / March 2, 2018 / Jaguar Health, Inc. (JAGX) (Jaguar or the Company), a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis, announced today that Napo Pharmaceuticals, Inc. (Napo), Jaguar's wholly-owned human health subsidiary, has signed an agreement (the Agreement) with pharmacy services provider Transition Patient Services to help streamline and expand nationwide patient access to Mytesi® (crofelemer), Napo's FDA-approved, first-in-class anti-secretory human prescription drug.
Headquartered in Trevose, Pennsylvania, Transition Patient Services (TPS) is a direct-to-patient hub-service pharmacy licensed in all 50 states and dedicated to simplifying medication access, increasing patient engagement, reducing prescription abandonment, and enhancing patient outcomes through confirmed medication acquisition and improved adherence.
Under the terms of the Agreement, TPS will operate a nationwide pilot program for Mytesi®, expected to begin this March. The core benefits of the program, named Mytesi Direct™, include streamlining prescription fulfillment for Mytesi® in order to ensure that Mytesi® users receive their prescription quickly, coordinating with other Napo programs - such as the Mytesi® Copay Savings Card and the NapoCares™ Patient Assistance Program - to help ensure that patient out-of-pocket expenses for Mytesi® are as low as possible, and improving Mytesi® refill adherence through the transmission of renewal reminders to patients.
Providers, pharmacists and their staff are also able to fill out prior authorization requests electronically for Mytesi® to simplify and streamline the prior authorization process.
"We're very pleased to have entered into this Agreement with TPS. We expect the Mytesi Direct™ program to significantly reduce barriers to Mytesi® access, acquisition and adherence in a highly patient-friendly and prescriber-friendly manner - helping us expand the number of patients able to benefit from the novel, first-in-class anti-secretory mechanism of action of Mytesi®, the only antidiarrheal studied in and U.S. FDA-approved for the symptomatic relief of noninfectious diarrhea in adults living with HIV/AIDS on antiretroviral therapy," Lisa Conte, Jaguar's President and CEO, stated.
"At Jaguar and Napo, our paramount focus is on driving Mytesi® sales. We remain confident that Mytesi® has the metrics and performance to be a successful, first-in-class entry to gastrointestinal supportive care in the HIV community and the ability to exhibit long-term sales growth, and we currently anticipate that Mytesi® gross sales for the period of January 1, 2017 through March 31, 2018 will total approximately $3.2 million. With the goal of continuing to drive Mytesi® sales and awareness nationwide, our plans for 2018 include new and extensive sales and marketing programs, advertising and promotional activities, a more than 80% expansion in the size of the Mytesi® sales team - which was recently increased to eleven highly-trained sales representatives and a national sales manager, direct-to-patient hub-service activities, the expected publication of supplemental data, and an increased focus on patient empowerment and educational programs for the important and neglected comorbidity of diarrhea in people living with HIV."
About Mytesi®
Mytesi® (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
About Jaguar Health, Inc.
Jaguar Health, Inc. is a commercial stage natural-products pharmaceuticals company focused on developing novel, sustainably derived gastrointestinal products on a global basis. Our wholly-owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
For more information about Jaguar, please visit jaguar.health. For more information about Napo, visit napopharma.com.
8k out, paid off debt in cash!!!
Wash rinse repeat
Still watching and waiting
2.65 pre market
Up to .1573 pre market
Look for a run up on Earnings!
He posts the videos to get people to his website so they either buy his courses and/or sign up for his inner circle chat group
Thinking this could push .25-.30 next week on earnings anticipation!
Chart looking similar to yesterday’s!
JAGX looking ready for a big breakout
Handle forming now, bullish signal
JAGX cup and handle forming
Quick jump up!
Earnings coming up, wouldn’t be surprised to see this get to .20+ prior to R/S. Vote isn’t until March, and wouldn’t take effect until June. They need the share price as high as possible to make the R/S worth it.
8 form 4s filed for a total of 1,325,000 shares @ 1.16 valued at $1,537,000
That link didn’t have any date or info regarding Earnings, just technical analysis
Do you have a link to that date?
Today is 2/5/18
POWER HOUR GONNA RIP!
JAGX going to .30+ this week! $1 Next week with earnings report!!!!
Volume before price!
Crazy volume today
Says cached, FDA updates at noon so file will be updated later today IMO
BOOM FDA 510(k) premarket notification!!!!!
https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm?id=k050338
New HOD .4545!!!! Weeeeee
.42 hit let’s gooooo